Why is Sunpharma increasing?
Table of Contents
Why is Sunpharma increasing?
Sun Pharma’s 10 per cent rise came after the company’s firm but lower-than-expected numbers for the quarter ended June. More importantly, the gains came as the company suggested that its arm has finally settled a multi-year antitrust lawsuit with the US government.
ICICI Securities has buy call on Sun Pharmaceutical Industries with a target price of Rs 959. The current market price of Sun Pharmaceutical Industries is Rs 802.5.
Will Sunpharma shares increase?
Stock is rising and might rise more. Stock of Sun Pharmaceuticals (SUNPHARMA) is trading above an important moving average line, but it crossed this line recently, which means that it could show a small or a large fall soon enough depending on its trend….
| Resistance | 792.2 |
|---|---|
| Support | 718.34 |
| Support | 699.59 |
Is Sun Pharma a good company?
Enhancement of knowledge and skills. Working at Sun pharma enhanced my knowledge, interpersonal and managerial skills. Work culture is good. Bus services are provides to all employees.
Is Sun Pharma overvalued?
Price to Book Ratio PB vs Industry: SUNPHARMA is overvalued based on its PB Ratio (3.7x) compared to the IN Pharmaceuticals industry average (2.8x).
Why Sun Pharma is in loss?
Read more news on During the quarter, the company reported a one-time exceptional loss of Rs 631 crore in relation to payments made for settlement of antitrust litigations filed by the US Department of Justice against arm Taro Pharmaceutical Industries as well as impairment of certain assets.
What is the intrinsic value of Sun Pharma?
What is the Intrinsic Value of SUN PHARMA ADVANCED RESEARCH COMPANY? As on 17-Dec-2021, the Intrinsic Value of SUN PHARMA ADVANCED RESEARCH COMPANY is Rs. 100.79 determined based on Median of the 3 historical models.
Why is nifty Pharma falling?
Benchmark indices Sensex and Nifty opened weaker on Monday due to losses in pharmaceutical stocks. Indian shares fell on Monday, weighed down by losses in pharmaceutical stocks, although shares of Pfizer Inc’s Indian arm jumped on positive data for the parent firm’s experimental pill against COVID-19.